Skip to main content

Practice

Sinusitis Activity Linked to Brain Dysfunction

Apr 13, 2021

Have you wondered why fibromyalgia, fatigue or cognitive dysfunction often co-associate with chronic sinusitis?



A case-control study of 22 patients with chronic rhinosinusitis published in JAMA Otolaryngology–Head and Neck Surgery found that sinonasal inflammation was

Read Article

IL-23 Targeting for Enthesitis in Psoriatic Arthritis

MedPage Today
Apr 13, 2021

Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found.



At week 24, 45% of patients receiving subcutaneous guselkumab every 4 weeks and 50% of those given the medication

Read Article

Low Risk of Malignancy with Secukinumab

Apr 12, 2021

Analysis of ongoing safety from the secukinumab (SEC) drug development program shows a low risk for malignancy in SEC patients treated for up to five years for either psoriasis, psoriatic arthritis (PsA) or ankylosing spondylitis (AS).



Safety data from 10,685 psoriasis, 2,523 PsA and

Read Article

DMARD Dropouts During COVID-19

Apr 12, 2021

A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do

Read Article

Anti-inflammatory Diet Control of Rheumatoid Arthritis

Apr 09, 2021

The TOMORROW study assessed the relationship between diet and disease activity in rheumatoid arthritis (RA) patients and has shown that RA patients are more likely to have higher inflammatory diets, but that a change to an anti-inflammatory diet resulted in lower disease activity scores.

Read Article

RheumNow Podcast – Mistakes with Steroids

Apr 08, 2021

Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.

Read Article

Overview of New VEXAS Syndrome

Apr 08, 2021

Medscape offers up an informative overview of the newly described syndrome called VEXAS discovered by researchers at the National Institutes of Health. These patients were previously misdiagnosed with Sweets syndrome, relapsing polychondritis, myelodysplastic syndrome, MGUS, or polyarteritis

Read Article

GLP-1 Therapy in Knee Osteoarthritis

Apr 08, 2021

Knee osteoarthritis is best managed by weight loss, as the effects of most analgesic therapies have been marginal and debatable. The use of anti-diabetic glucagon-like peptide-1 therapies have demonstrated significant weight loss benefits; hence this trial evaluated the potential weight loss and

Read Article

Can Targeting RANKL in RA Heal Erosions?

MedPage Today
Apr 07, 2021

Treatment with denosumab (Prolia) helped heal bone erosions over 2 years among patients with rheumatoid arthritis whose disease activity was well controlled, researchers reported.

Read Article

Implementing Smoking Cessation Programs

Apr 07, 2021

Rheumatologists are keen to the effects of smoking (increased arthritis risk, worse outcomes, blunted DMARD responses, added cardiopulmonary risks), but often do not have the resources or plan to encourage or implement smoking cessation from the rheumatology clinic. A new study details the

Read Article

Rheumatology Care Derailed by COVID-19

Apr 06, 2021

A survey study from the  ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.



Data from the ArthritisPower Patient-Powered Research Network and CreakyJoints patient community were gathered by

Read Article

Reactogenicity Following mRNA COVID-19 Vaccines

Apr 06, 2021

JAMA has published the real-world reporting of mRNA vaccine side effects (reactogenicity) gathered from CDC V-safe Surveillance system and shows that local and systemic reactions were often mild and transient and most commonly seen during the first day following their second dose.

Read Article

Cost Efficacy of Knee Replacement in Obese Osteoarthritis

Apr 05, 2021

Total knee replacement (TKR) in obese patients with end-stage knee osteoarthritis appears to be a beneficial and cost-effective strategy for treating. The only potential limitation is a greater risk for adverse events in those with a body mass index (BMI) of 40 kg/m2 or greater.

Read Article

Rituximab in Systemic Sclerosis?

Apr 05, 2021

No drug is FDA approved to manage the skin or joint complaints of systemic sclerosis (SSc); a recent metanalysis suggests that rituximab may improve skin score and disease activity indices (DAS, mRSS) while stabilizing organ involvement in SSc patients.

Read Article

RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

Apr 02, 2021

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Read Article

US Senate Introduces the Safe Step Act

ACR
Apr 01, 2021

The American College of Rheumatology (ACR) today commended leaders in the United States Senate for introducing the bipartisan Safe Step Act of 2021 (S. 464), new legislation that would place reasonable limits on insurer use of step therapy. This troubling practice requires patients to first

Read Article

Upadacitinib Clinical Efficacy in Psoriatic Arthritis

Apr 01, 2021

McInnes and colleagues have published the results of the SELECT - PsA trial in NEJM showing updacitinib (UPA) to be superior to placebo in active psoriatic arthritis (PsA) patients, with 15 mg UPA equal to adalimumab (ADA) and 30 mg UPA qd being superior to ADA.



Janus kinase

Read Article

Inflammatory Conditions Up the Risk of Premature Myocardial Infarction

Mar 31, 2021

The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.



Data derived from the retrospective

Read Article

Aortic Calcification and Lumbar Fracture Risk in Older Men

Mar 30, 2021

Fractures of the spine and abdominal aortic calcification (AAC) can both be visualized with spinal imaging; a new report shows that finding both radiographic vertebral fracture and AAC on the same lateral spine images may predict the risk of future incident major osteoporotic fracture in

Read Article

Hypertension Unaffected by Urate Lowering Therapy

Mar 30, 2021

Does uric acid contribute to the risk of hypertension (HTN)?  A recent cohort trial shows that allopurinol in young adults does not sufficiently lower blood pressure (BP).



Previous research in a small cohort of obese hypertensive kids showed that urate lowering therapy was assoaciated

Read Article

Psoriatic Disease Management - RNL 2021 Highlights

Mar 29, 2021

This year’s coverage of psoriatic arthritis was once again, both exciting and informative. Topics included an overview of the latest therapeutic options, an excellent discussion on psoriasis specifically, and the epidemiology of psoriatic arthritis. 

Read Article

Serious Infections Still Common in Vasculitis

MedPage Today
Mar 29, 2021

Serious infections occurred more frequently among patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis who were given induction therapy with cyclophosphamide compared with rituximab (Rituxan), Greek researchers found.

Read Article
Are You a Super Rheum? https://t.co/omvQXwhcoV https://t.co/8iQaRAi5di
Dr. John Cush @RheumNow( View Tweet )
Mar 26, 2021

RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)

Mar 26, 2021

Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.




  1. Analysis of CPRD registry and 15,670 MTX treated pts (46,571 PYs) showed discontinuation for abnormal or severely abnormal labs was 42/1000PY and 6/1,000PY and half that

Read Article

FDA Panel Rejects Tanezumab for Osteoarthritis

Mar 25, 2021

A two day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab, a nerve growth factor inhibitor, for use in osteoarthritis (OA).



Tanezumab (TAN) has been developed by Pfizer and Eli Lilly over the

Read Article
×